Hydagelan (Hydromorphone Hydrochloride)

Hydagelan is indicated for the treatment of pain that is moderate to severe and not adequately controlled by non‑opioid analgesics. Clinical use includes several common pain scenarios.

• Moderate to severe acute pain, such as trauma or injury‑related pain.
• Post‑operative pain following surgical procedures.
• Cancer‑related pain requiring opioid therapy.
• Pain associated with severe musculoskeletal conditions when other treatments are insufficient.
• Breakthrough pain in patients already receiving opioid maintenance therapy.

• Hydromorphone hydrochloride exerts its analgesic effect by acting as a full agonist at the central µ‑opioid receptors. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and enhances potassium efflux, leading to decreased neuronal excitability and suppression of pain signal transmission in the spinal cord and brain. The resulting modulation of nociceptive pathways produces both analgesia and sedation.

Adverse reactions to Hydagelan may vary in frequency and severity. The following lists have been grouped by how often they are reported in clinical practice.

Common

• Nausea, vomiting, or loss of appetite.
• Constipation or reduced bowel motility.
• Drowsiness, fatigue, or mild dizziness.
• Dry mouth and mild sweating.
• Itching or mild skin rash.
• Blurred vision or visual disturbances.

Serious

• Respiratory depression or shallow breathing.
• Severe hypotension or cardiovascular collapse.
• Marked sedation leading to impaired consciousness.
• Development of physical dependence or withdrawal syndrome upon abrupt discontinuation.
• Seizures or convulsions, especially in high doses or rapid escalation.
• Anaphylactic or severe allergic reactions, including airway swelling and hypotension.

When prescribing or using Hydagelan, clinicians and patients should observe several precautionary measures to minimize risk and ensure safe therapy.

• Assess the patient’s respiratory function before initiating therapy and monitor regularly during treatment.
• Use the lowest effective dose for the shortest duration necessary to achieve pain control.
• Avoid use in individuals with known hypersensitivity to hydromorphone or other opioid analgesics.
• Exercise caution in patients with a history of substance use disorder or dependence.
• Consider alternative analgesics in pregnant or breastfeeding women, as safety data are limited.
• Review concomitant medications for potential additive central nervous system depression.

Hydagelan can interact with other medicines, altering its effectiveness or increasing the risk of adverse events. Interactions are grouped by the level of clinical concern.

Avoid

• Concurrent use with other strong opioids or high‑dose opioid agonists.
• Co‑administration with potent central nervous system depressants such as benzodiazepines, barbiturates, or alcohol.
• Combination with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy.

Use with caution

• Concomitant use of serotonergic agents (e.g., SSRIs, SNRIs, tramadol) due to risk of serotonin syndrome.
• Concurrent administration of CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which may increase hydromorphone plasma levels.
• Use with CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce analgesic effect.